[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @janthecurious1 Jan Jan posts on X about $nvo, health, business, momentum the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1471510678561169415/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +286% - X Year XXXXXXX +112% ### Mentions: X [#](/creator/twitter::1471510678561169415/posts_active)  - X Week X -XX% - X Month XX -XX% - X Months XXX +247% - X Year XXX +116% ### Followers: XXX [#](/creator/twitter::1471510678561169415/followers)  - X Week XXX no change - X Month XXX +2.10% - X Months XXX +24% - X Year XXX +28% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1471510678561169415/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [countries](/list/countries) XXXXX% **Social topic influence** [$nvo](/topic/$nvo) #93, [health](/topic/health) 28.57%, [business](/topic/business) 14.29%, [momentum](/topic/momentum) 14.29%, [denmark](/topic/denmark) 14.29%, [dec](/topic/dec) 14.29%, [novo](/topic/novo) XXXXX% **Top assets mentioned** [Novo-Nordisk (NVO)](/topic/$nvo) ### Top Social Posts Top posts by engagements in the last XX hours "#Novonordisk $nvo The market is sleeping on what may be the biggest shift since Wegovy. Amycretin is emerging as the true next-generation breakthrough - stronger data broader potential and far harder to copy. And the oral version is already showing the kind of efficacy that can rewrite the entire obesity and diabetes landscape. With accelerated U.S. pathways now on the table the timeline for a first-in-class oral successor looks far more favorable than the market assumes. This is the early stage of a multi-year rerating. The upside is massive - and absolutely not priced in" [X Link](https://x.com/janthecurious1/status/1995489202780127318) 2025-12-01T13:44Z XXX followers, XXX engagements "#Novonordisk $nvo After regulators rejected it twice the situation has completely changed. With WHOs approval now in place they simply cant ignore it - and I believe this could create significant momentum potentially even a major boost in 2026. With prices coming down the business case finally makes sense for both governments and Novo. In the EU more than half of adults are overweight and around XX% are obese. Thats a massive addressable population putting enormous pressure on national healthcare systems. If this approval spreads across the EU as expected it could turn into a genuine win-win:" [X Link](https://x.com/janthecurious1/status/1996121333898301939) 2025-12-03T07:36Z XXX followers, XXX engagements "#novonordisk $nvo WHOs backing of GLP-1 is a global game-changing signal. Were looking at a trillion-dollar health market now getting regulatory tailwinds. Novo is already at the epicenter of this structural megatrend. I believe the market still underestimates how early we are in this curve. 🚀🚀🚀" [X Link](https://x.com/janthecurious1/status/1995519327043223790) 2025-12-01T15:44Z XXX followers, XXX engagements "#novonordisk $nvo Novo Nordisk says its too early to call game over in Alzheimers. Semaglutide shows biological effect but not enough to change symptoms - research continues. Source: Brsen Denmark 2025. Dec. 4" [X Link](https://x.com/janthecurious1/status/1996463740024406224) 2025-12-04T06:17Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@janthecurious1 Jan
Jan posts on X about $nvo, health, business, momentum the most. They currently have XXX followers and X posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +286%
- X Year XXXXXXX +112%
Mentions: X #
- X Week X -XX%
- X Month XX -XX%
- X Months XXX +247%
- X Year XXX +116%
Followers: XXX #
- X Week XXX no change
- X Month XXX +2.10%
- X Months XXX +24%
- X Year XXX +28%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% countries XXXXX%
Social topic influence $nvo #93, health 28.57%, business 14.29%, momentum 14.29%, denmark 14.29%, dec 14.29%, novo XXXXX%
Top assets mentioned Novo-Nordisk (NVO)
Top Social Posts
Top posts by engagements in the last XX hours
"#Novonordisk $nvo The market is sleeping on what may be the biggest shift since Wegovy. Amycretin is emerging as the true next-generation breakthrough - stronger data broader potential and far harder to copy. And the oral version is already showing the kind of efficacy that can rewrite the entire obesity and diabetes landscape. With accelerated U.S. pathways now on the table the timeline for a first-in-class oral successor looks far more favorable than the market assumes. This is the early stage of a multi-year rerating. The upside is massive - and absolutely not priced in"
X Link 2025-12-01T13:44Z XXX followers, XXX engagements
"#Novonordisk $nvo After regulators rejected it twice the situation has completely changed. With WHOs approval now in place they simply cant ignore it - and I believe this could create significant momentum potentially even a major boost in 2026. With prices coming down the business case finally makes sense for both governments and Novo. In the EU more than half of adults are overweight and around XX% are obese. Thats a massive addressable population putting enormous pressure on national healthcare systems. If this approval spreads across the EU as expected it could turn into a genuine win-win:"
X Link 2025-12-03T07:36Z XXX followers, XXX engagements
"#novonordisk $nvo WHOs backing of GLP-1 is a global game-changing signal. Were looking at a trillion-dollar health market now getting regulatory tailwinds. Novo is already at the epicenter of this structural megatrend. I believe the market still underestimates how early we are in this curve. 🚀🚀🚀"
X Link 2025-12-01T15:44Z XXX followers, XXX engagements
"#novonordisk $nvo Novo Nordisk says its too early to call game over in Alzheimers. Semaglutide shows biological effect but not enough to change symptoms - research continues. Source: Brsen Denmark 2025. Dec. 4"
X Link 2025-12-04T06:17Z XXX followers, XXX engagements